A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities

Journal of Investigative Medicine

Volumn 44, Issue 9, 1996, Pages 522-530

  Quinn, Charles T ^a   Kamen, Barton A ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; BIOPTERIN; FOLIC ACID ANTAGONIST; HOMOCYSTEINE; METHOTREXATE; NUCLEIC ACID SYNTHESIS INHIBITOR;

ACUTE DISEASE; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; CLASSIFICATION; HUMAN; METABOLISM; NEUROLOGIC DISEASE; REVIEW;

ACUTE DISEASE; ADENOSINE; BIOPTERIN; CHRONIC DISEASE; FOLIC ACID ANTAGONISTS; HOMOCYSTEINE; HUMANS; METHOTREXATE; NERVOUS SYSTEM DISEASES; NUCLEIC ACID SYNTHESIS INHIBITORS;

EID: 0030332505     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (106)

1. Jonsson OG, Kamen BA. Methotrexate and leukemia. Cancer Invest 1991;9:53-60.
2. Gay CT, Bodensteiner JB, Nitschke R, Sexauer C, Wilson D. Reversible treatment-related leukoencephalopathy. J Child Neurol 1989;4:208-13.
3. Allen JC, Rosen G, Mehta BM, Horten B. Leukoencephalopathy following high-dose IV methotrexate chemotherapy with leucovorin rescue. Cancer Treat Rep 1980;64:1261-73.
4. Jaffe N, Takaue Y, Anzai T, Robertson R. Transient neurologic disturbances induced by high-dose methotrexate treatment. Cancer 1985;56:1356-60.
5. Walker RW, Allen JC, Rosen G, Caparros B. Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 1986;4:1845-50.
6. Kay HE, Knapton PJ, O'Sullivan JP, Wells DG, Harris RF, Innes EM, Stuart J, Schwartz FC, Thompson EN. Enoephalopathy in acute leukaemia associated with methotrexate therapy. Arch Dis Child 1972;47:344-54.
7. Cronstein BN, Eberle MA, Gruber HE., Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA 1991;88:2441-5.
8. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosyl-aminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 1985;82:4881-5.
9. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimi-dazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polygultamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986;236:193-200.
10. Cronstein BN, Naime D, Ostad E. The anti-inflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-82.
11. Bernini JC, Fort DW, Griener JC, Kane BJ, Chappell WB, Kamen BA. Aminophylline for methotrexate-induced neurotoxicity. Lancet 1995;345:544-7.
12. Rall TW. Drugs used in the treatment of asthma. In: Gilman AG, Rall TW, Nies A, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York: Pergamon Press, 1990:618-37.
13. Jacobson KA, Trivedi BK, Churchill PC, Williams M. Novel therapeutics acting via purine receptors. Biochem Pharmacol 1991;41:1399-1410.
14. Calabresi P, Chabner B. Antineoplastic agents. In: Gilman AG, Rall TW, Nies A, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York: Pergamon Press, 1990:1209-63.
15. Kane BJ, Kuhn JG, Roush MK. Pentostatin: an adenosine deaminase inhibitor for the treatment of hairy cell leukemia. Ann Pharmacother 1992;26:939-47.
16. Cotton RGH. Additional rescue from methotrexate toxicity? Lancet 1978;2(8087):484.
17. Abelson HT. Methotrexate and central nervous system toxicity. Cancer Treat Rep 1978;62:1999-2001.
18. Blau N, Curtius HC, Kierat L, Leupold D, Kohne E. Hyperphenylalaninemia caused by dihydropteridine reductase deficiency in children receiving chemotherapy for acute lymphoblastic leukemia. J Pediatr 1989;115:661-2.
19. Botez MI, Young SN, Bachevalier J, Gauthier S. Folate deficiency and decreased brain 5-hydroxytryptamine synthesis in man and rat. Nature 1979;278:182-3.
20. Bottiglieri T, Hyland K, Laundy M, Godfrey P, Carney MWP, Toone BK, Reynolds EH. Folate deficiency, biopterin, and monoamine metabolism in depression. Psychol Med 1992;22:871-6.
21. Hyland K, Smith I, Bottiglieri T, Perry J, Wendel U, Clayton PT, Leonard JV. Demyelination and decreased S-adenosylmethionine in 5, 10-methylenetetrahydrofolate reductase deficiency. Neurology 1988;38:459-62.
22. Surtees R, Heales S, Bowron A. Association of cerebrospinal fluid deficiency of 5-methyltetrahydrofolate, but not S-adenosylmethionine, with reduced concentrations of the acid metabolites of 5-hydroxytryptamine and dopamine. Clin Sci (Colch) 1994;86:697-702.
23. Millot F, Dhondt JL, Hayte JM, Bauters F. Impairment of cerebral biogenic amine synthesis in a patient receiving high-dose methotrexate. Am J Pediatr Hematol Oncol 1992;14:276-8.
24. 2 intravenous methotrexate. Pediatr Res 1995;37:151-4.
25. Johnston MV, Silverstein FS, Greenberg H, Knutsen CA, Chandler W, Phillips T, Ensminger WD. Effects of intraventricular methotrexate on cerebrospinal fluid monoamine metabolites in rhesus monkeys. Cancer Treat Rep 1986;70:1205-9.
26. Silverstein FS, Hutchinson RJ, Johnston MV. Cerebrospinal fluid biogenic amine metabolites in children during treatment for acute lymphocytic leukemia. Pediatr Res 1986;20:285-91.
27. Silverstein FS, Johnston MV. A model of methotrexate encephalopathy: neurotransmitter and pathologic abnormalities. J Child Neurol 1986;1:351-7.
28. Nichol CA, Lee CL, Edelstein MP, Chao JY, Duch DS. Biosynthesis of tetrahydrobiopterin by de novo and salvage pathways in adrenal medulla extracts, mammalian cell cultures, and rat brain in vivo. Proc Natl Acad Sci USA 1983;80:1546-50.
29. Smith I, Howells DW, Hyland K. Pteridines and mono-amines: relevance to neurological damage. Postgrad Med J 1986;62:113-23.
30. Kaufman S. Studies on the structure of the primary oxidation product formed from tetrahydropteridines during phenylalanine hydrox-ylation. J Biol Chem 1964;239:332-8.
31. Kaufman S. Metabolism of the phenylalanine hydroxylation cofactor. J Biol Chem 1967;242:3934-43.
32. Matthews RG, Kaufman S. Characterization of dihydropterin reductase activity of pig liver methylenetetrahydrofolate reductase. J Biol Chem 1980;255:6014-7.
33. Craine JE, Hall ES, Kaufman S. The isolation and characterization of dihydropteridine reductase from sheep liver. J Biol Chem 1972;247:6082-91.
34. Liang BT, Vaccaro KK, Perelle BA, Perlman RL. Studies on dihydropteridine reductase activity in pheochromocytoma cells. J Neurochem 1981;37:1164-9.
35. Kaufman S. Some metabolic relationships between biopterin and folate: implications for the "methyl trap hypothesis." Neurochem Res 1991;16:1031-6.
36. Kaufman S, Levenberg B. Further studies on the phenylalanine-hydroxylation cofactor. J Biol Chem 1959;234:2683-8.
37. Goodfriend TL, Kaufman S. Phenylalanine metabolism and folic acid antagonists. J Clin Invest 1961;40:1743-50.
38. Milstien S, Kaufman S. Studies on the phenylalanine hydroxylase system in liver slices. J Biol Chem 1975;250:4777-81.
39. Watson BM, Schlesinger P, Cotton RGH. Dihydroxanthopterinuria in phenylketonuria and lethal hyperphenylalaninemia patients. Clin Chim Acta 1977;78:417-23.
40. Duch DS, Lee CL, Edelstein MP, Nichol CA. Biosynthesis of tetrahydrobiopterin in the presence of dihydrofolate reductase inhibitors. Mol Pharmacol 1983;24:103-8.
41. Culvenor AJ, Miller LP, Levine RA, Lovenberg W. Effects of methotrexate on biopterin levels and synthesis in rat cultured pineal glands. J Neurochem 1984;42:1707-14.
42. Millot F, Chastagner P, Dhondt J, Sommelet D. Substitutive therapy in a case of methotrexate neurotoxicity. Eur J Cancer 1992;28A:1935.
43. 6, and folate on blood homocysteine levels. Ann N Y Acad Sci 1992;669:197-204.
44. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. New York: McGraw Hill, Inc., 1995:1279-327.
45. Refsum H, Helland S, Ueland PM. Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving low-dose methotrexate treatment. Clin Pharmacol Ther 1989;46:510-20.
46. Refsum H, Ueland PM, Kvinnsland S. Acute and long-term effects of high-dose methotrexate treatment on homocysteine in plasma and urine. Cancer Res 1986;46:5385-91.
47. Broxson EH, Stork LC, Allen RH, Stabler SP, Kolhouse JF. Changes in plasma methionine and total homocysteine levels in patients receiving methotrexate infusions. Cancer Res 1989;49:5879-83.
48. Refsum H, Wesenberg F, Ueland PM. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991;51:828-35.
49. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GHJ, Bromberg IL, Cerone R, Fowler B, Grobe H, Schmidt H, Schweitzer L. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 1985;37:1-31.
50. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
51. Brattstrom LE, Hardebo JE, Hultberg BL. Moderate hyperhomocystinemia - a possible risk factor for arteriosclerotic cerbrovascular disease. Stroke 1984;15:1012-6.
52. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990;21:572-6.
53. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-8.
54. Genest JJ Jr, McNamara JR, Salem DN, Wilson PWF, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990;16:1114-9.
55. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-9.
56. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. Circulation 1993;87:1107-13.
57. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PWF, Belanger MA, O'Leary DH, Wolf PA, Schaeffer EJ, Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995;332:286-91.
58. den Heijer M, Blom HJ, Gerrits WB, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995;345:882-5.
59. Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993;71:337-59.
60. Malinow MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med 1994;236:603-17.
61. Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia: vascular injury and arterial thrombosis. N Engl J Med 1974;291:537-43.
62. Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976;58:731-41.
63. Tsai J-C, Perrella MA, Yoshizumi M, Hsieh C-M, Haber E, Schlegel R, Lee M-E. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369-73.
64. Tsai, JC, Wang H, Perrella MA, Yoshizumi M, Sibinga NES, Tan LC, Haber E, Chang TH-T, Schlegel R, Lee M-E. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 1996;97:146-53.
65. Giannini MJ, Coleman M, Innerfield I. Antithrombin activity in homocystinuria. Lancet 1975;1(7915):1094.
66. Palareti G, Salardi S, Piazzi S, Legnani C, Poggi M, Grauso F, Caniato A, Coccheri S, Cacciari E. Blood coagulation changes in homocystinuria: effects of pyridoxine and other specific therapy. J Pediatr 1986;109:1001-6.
67. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990;75:895-901.
68. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991;88:1906-14.
69. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial activator. J Clin Invest 1986;77:1909-16.
70. Rodgers GM, Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA. Homocysteine, a risk factor for vascular disease and thrombosis, induces tissue factor activity in endothelial cells [abstract]. Clin Res 1993;41(1):19A.
71. Harker LA, Scott CR. Platelets in homocystinuria. N Engl J Med 1977;296:818.
72. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992;89:10193-7.
73. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-18.
74. Winick NJ, Bowman WP, Kamen BA, Roach ES, Rollins N, Jacaruso D, Buchanan GR. Unexpected neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst 1992;84:252-6.
75. Phanthumchinda K, Intragumtornchai T, Kasantikul V. Stroke-like syndrome, mineralizing microangiopathy, and neuroaxonal dystrophy following intrathecal methotrexate therapy. Neurology 1991;41:1847-8.
76. Yim YS, Mahoney DH, Oshman DG. Hemiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphocytic leukemia. Cancer 1991;67:2058-61.
77. Kang SS, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988;43:414-21.
78. Brattstrom LE, Israelsson B, Jeppson JO, Hultberg BL. Folic acid - an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988;48:215-21.
79. Smolin LA, Benevenga NJ, Berlow S. The use of betaine for the treatment of homocystinuria. J Pediatr 1981;99:467-72.
80. Wilcken DEL, Wilcken B, Dudman NPB, Tyrrell PA. Homocystinuria - the effects of betaine in patients not responsive to pyridoxine. N Engl J Med 1983;309:448-53.
81. Kishi T, Kawamura I, Harada Y, Eguchi T, Sakura N, Ueda K, Narisawa K, Rosenblatt DS. Effect of betaine on S-adenosylmethionine levels in the cerebrospinal fluid in a patient with methylenetetrahydrofolate reductase deficiency and peripheral neuropathy. J Inherit Metab Dis 1994;17:560-5.
82. Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med 1995;332:328-9.
83. Ohmori S, Kodama T, Ikegama T, Mizuhara S. Unusual sulfur-containing amino acids in the urine of homocystinuric patients: III. Homocysteic acid, homocysteine sulfinic acid, S-(carboxymethylthio)homocysteine, and S-(3-hydroxy-3-carboxy-n-propyl)homocysteine. Physiol Chem Phys Med NMR 1972;4:286-94.
84. Frauscher G, Karnaukhova E, Muehl A, Hoeger H, Lubec B. Oral administration of homocysteine leads to increased plasma triglycerides and homocysteic acid - additional mechanisms in homocysteine-induced endothelial damage. Life Sci 1995;57:813-7.
85. Griffiths R. Cysteine sulphinate (CSA) as an excitatory amino acid transmitter candidate in the mammalian central nervous system. Prog Neurobiol 1990;35:313-23.
86. Do KQ, Herrling PL, Streit P, Cuenod M. Release of neuroactive substances: homocysteic acid as an endogenous agonist of the NMDA receptor. J Neural Transm 1988;72:185-90.
87. Cuenod M, Grandes P, Zangerle L, Streit P, Do KQ. Sulphur-containing excitatory amnio acids in intercellular communication. Biochem Soc Trans 1993;21:72-7.
88. Griffiths R. The biochemistry and pharmacology of excitatory sulphur-containing amino acids. Biochem Soc Trans 1993;21:66-72.
89. Turski WA. Homocysteic acid: convulsan: action of steroisomers in mice. Brain Res 1989;479:371-3.
90. Croucher MJ, Collins JF, Meldrum BS. Anticonvulsant action of excitatory amino acid antagonists. Science 1982;216:899-901.
91. Meldrum B. Excitatory amino acid antagonists as potential therapeutic agents. In: Jenner P, ed. Neurotoxins and their pharmacological implications New York: Raven Press, 1987:33-53.
92. Meldrum B, Millan M, Patel S, de Sarro G. Antiepileptic effects of focal microinjection of excitatory amino acid antagonists. J Neural Transm 1988;72:191-200.
93. Grieco AJ. Homocystinuria: pathogenetic mechanisms. Am J Med Sci 1977;273:120-32.
94. Bridges RJ, Hatalski CG, Shim SN, Cummings BJ, Vijayan V, Kundi A, Cotman CW. Gliotoxic actions of excitatory amino acids. Neuropharmacology 1992;31:899-907.
95. Lipton SA, Rosenberg PA. Mechanisms of disease: excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330:613-22.
96. Santhosh-Kumar CR, Hassell KL, Deutsch JC, Kolhouse JF. Are neuropsychiatrie manifestations of folate, cobalamin and pyridoxine deficiency mediated through imbalances in excitatory sulfur amino acids? Med Hypotheses 1994;43:239-44.
97. Martin DW Jr, Gelfand EW. Biochemistry of diseases of immunodevelopment. Annu Rev Biochem 1981;50:845-77.
98. Franklin PH, Tripp ED, Zhang G, Gale K, Murray TF. Adenosine receptor activation blocks seizures induced by bicuculline methiodide in the rat prepiriform cortex. Eur J Pharmacol 1988;150:207-9.
99. Gregorios JB, Soucy D. Effects of methotrexate on astrocytes in primary culture: light and electron microscopic studies. Brain Res 1990;516:20-30.
100. Bruce-Gregorios JH, Soucy D, Chen MG, Benson N. Effect of methotrexate on cell cycle and DNA synthesis of astrocytes in primary culture: flow cytometric studies. J Neuropathol Exp Neurol 1991;50:63-72.
101. Gilbert MR, Harding BL, Grossman SA. Methotrexate neurotoxicity: in vitro studies using cerebellar explants from rats. Cancer Res 1989;49:2502-5.
102. Hill RG, Miller AA. Antagonism by folic acid of presynaptic inhibition in the rat cuneate nucleus. Br J Pharmacol 1974;50:425-7.
103. Ruck A, Kramer S, Metz J, Brennan MJW. Methyltetrahydrofolate is a potent and selective agonist for kainic acid receptors. Nature 1980;287:852-3.
104. Olney JW, Fuller TA, de Gubareff T. Kainate-like neurotoxicity of folates. Nature 1981;292:165-7.
105. Otis LC, Madison DV, Nicoll RA. Folic acid has a disinhibitory action in the rat hippocampal slice preparation. Brain Res 1985;346:281-6.
106. Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 1994;48:137-52.